Catalyst Pharmaceuticals, Inc. — Cyborg Score 8/10
Strong
Specialty Pharmaceuticals / Rare Diseases
Strategic Profile
Catalyst's strategy centers on in-licensing proven therapies and expanding their market penetration through commercial execution and lifecycle management. The company markets FIRDAPSE (amifampridine) for Lambert-Eaton Myasthenic Syndrome, AGAMREE (vamorolone) for Duchenne Muscular Dystrophy, and FYCOMPA (perampanel) for epilepsy. With strong cash position ($709M) and disciplined business development, the company is positioned for continued organic growth while selectively pursuing development-stage acquisitions with established proof of concept.
Cyborg Score Rationale
Catalyst demonstrates solid financial momentum with record 2025 revenue growth of 19.8%, strong profitability (GAAP net income of $214.3M), and a substantial cash position. The diversified rare disease portfolio generates recurring revenue with durable margins, though reliance on marketed products limits explosive growth potential. Market analyst consensus is positive with average price target of $33.25 representing 41.8% upside.
Top Insights
Record 2025 revenue of $589M with 19.8% YoY growth and GAAP net income of $214.3M demonstrates scalable business model and strong commercial execution
2026 guidance of $615M-$645M revenue reflects continued momentum from core products FIRDAPSE ($435M-$450M) and AGAMREE ($140M-$150M), with expansion of diagnoses and payer coverage driving patient access
Strategic expansion of business development aperture to include development-stage assets with established proof of concept signals disciplined growth strategy beyond organic initiatives
Analyst consensus rates stock "Strong Buy" with 12-month price target of $33.25 (41.8% upside), reflecting confidence in rare disease portfolio strength and operational execution
Named Competitors
Amifampridine-related therapies — Competing LEMS treatment (orphan exclusivity was subject of FDA litigation)
Perampanel (seizure treatment) — Original developer of FYCOMPA perampanel for focal and tonic-clonic seizures
Vamorolone (DMD treatment) — Original developer of AGAMREE, licensed North American rights to Catalyst
Recent Developments
(February 2026) Catalyst reported record 2025 full-year revenue of $589.0 million, up 19.8% YoY, with GAAP net income of $214.3 million and cash of $709.2 million; provided 2026 revenue guidance of $615M-$645M
(August 2025) Achieved record Q2 2025 revenues of $146.6 million, up 19.4% YoY, marking consecutive quarterly growth across product portfolio
(May 2024) FDA approved supplemental NDA increasing maximum daily dose of FIRDAPSE from 80mg to 100mg for adults and pediatric patients weighing >45kg
Open the full interactive Catalyst Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.